DJIA 18,232.02 -53.72 -0.29%
NASDAQ 5,089.36 -1.43 -0.03%
S&P 500 2,126.06 -4.76 -0.22%
market minute promo

Targacept , Inc. (NASDAQ: TRGT)

2.66 0.15 (5.98%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

TRGT $2.66 5.98%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $2.52
Previous Close $2.51
Daily Range $2.46 - $2.68
52-Week Range $2.15 - $4.68
Market Cap $90.1M
P/E Ratio -3.44
Dividend (Yield) $0.00 (0.0%)
Volume 110,918
Average Daily Volume 65,553
Current FY EPS -$0.89

Sector

Healthcare

Industry

Drug Makers

Targacept , Inc. (TRGT) Description

A biopharmaceutical company engaged in the design, discovery and development of NNR Therapeutics, a new class of drugs for the treatment of multiple diseases and disorders of the central nervous system. Website: http://www.targacept.com/

News & Commentary Rss Feed

Keep an Eye on Biogen, Johnson & Johnson, and Merck Today

Biogen, Johnson & Johnson, and Merck could all make health care headlines this morning. Here’s all the news you need to know.

Targacept and Catalyst Biosciences Amend Definitive Merger Agreement

Targacept's Diabetic Gastroparesis Drug Fails to Impress - Analyst Blog

Targacept's Diabetic Gastroparesis Drug Fails to Impress - Analyst Blog

Targacept Announces Negative Top-Line Results from Exploratory Study of TC-6499 in Diabetic Gastropa

Targacept Announces Negative Top-Line Results from Exploratory Study of TC-6499 in Diabetic Gastroparesis

The Zacks Analyst Blog Highlights: Alkermes, Regulus, Juno Therapeutics, Targacept and Gilead - Pres

The Zacks Analyst Blog Highlights: Alkermes, Regulus, Juno Therapeutics, Targacept and Gilead - Press Releases

Biotech Stock Roundup: Alkermes Drug Fares Well, Targacept Slides on Deal Termination - Analyst Blo

Biotech Stock Roundup: Alkermes Drug Fares Well, Targacept Slides on Deal Termination - Analyst Blog

Targacept Crumbles as Pfizer Pulls Out of Collaboration - Analyst Blog

Why I Am Still Long Targacept After The Reverse Merger Announcement

Targacept Management Increases Urgency And Aims For Q4 Strategic Action

Targacept's (TRGT) CEO Dr. Stephen Hill on Q3 2014 Results - Earnings Call Transcript

See More TRGT News...

TRGT's Top Competitors

TRGT $2.66 (5.98%)
Current stock: TRGT
AMGN $163.59 (-0.15%)
Current stock: AMGN
GILD $111.71 (0.44%)
Current stock: GILD
BIIB $398.68 (-0.62%)
Current stock: BIIB